CR Pharma Negotiating for China Rights to Two Xbrane Candidates

CR Pharma, China 's second-largest drugmaker, is negotiating with Sweden 's Xbrane Biopharma for China rights to two Xbrane candidates. One of the drugs is Spherotide, a generic testosterone suppressor with an extended release delivery used to treat prostate cancer. The other is Xlucane, a biosimilar to Roche's Lucentis, a treatment for wet age-related macular degeneration. According to Xbrane, it has held final negotiations for China rights to Spherotide, though an agreement has not been signed. So far, it has agreed only to a non-binding letter of intent for Xlucane, with terms still to be discussed. More details.... Stock Symbol: (HK: 3320) Share this with colleagues: // // >